Back to results
US 2024/0200130 A1Published application
Highly sensitive in vitro assays to define substrate preferences and sites of nucleic-acid binding, modifying, and cleaving agents
AssigneeThe General Hospital Corporation
InventorsJ. Keith Joung, Vikram Pattanayak, Karl Petri
Life of this patent
Estimating the term…
Abstract
Methods and compositions for performing highly sensitive in vitro assays to define substrate preferences and off-target sites of nucleic-acid binding, modifying, and cleaving agents.
Claims20
1-2. (canceled)
A method of identifying double stranded DNA sequences that are modified by a base editing enzyme, the method comprising:
- (i) providing a plurality of linear dsDNA oligonucleotides of known sequences, each oligonucleotide having a 5′ end and a 3′ end and bearing two copies of a unique identifier sequence at or near both the 3′ and 5′ ends of the oligonucleotide, and a common sequence that is present in each one of the oligonucleotides in the plurality;
- (ii) incubating the plurality linear dsDNA oligonucleotides in the presence of a base editing enzyme under conditions sufficient for modification to occur;
- (iii) amplifying the oligonucleotides with a polymerase that converts edited base pairs to equal mixtures of canonical base pairs during DNA synthesis, optionally wherein a dATP nucleotide is incorporated across from dU or a dCTP nucleotide is incorporated across from dI, such that an oligonucleotide that has been modified by the base editing enzyme will be amplified as a mixture of the original barcode-linked sequence from the pre-treatment library and also a modified sequence that contains substitutions;
- and
- (iv) determining the sequences of the amplified oligonucleotides, thereby identifying double stranded DNA sequences that are modified by the base editing enzyme.
2 more elements
4-7. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.